<DOC>
	<DOCNO>NCT00270452</DOCNO>
	<brief_summary>This study test whether certain patient myelodysplastic syndrome ( MDS ) , acute myeloid leukemia ( AML ) chronic myeloid leukemia ( CML ) safely vaccinate two peptide vaccine derive protein call proteinase 3 ( PR1 ) Wilm 's tumor-1 ( WT1 ) . These protein produce large amount cell MDS , AML CML patient . The peptide combine `` adjuvant '' call Montanide make vaccine , vaccine give GM-CSF ( sargramostim ) . Both Montanide sargramostim help immune system respond vaccine . The vaccine activate immune system make specialized cell search kill MDS , AML CML cell contain two protein . Patients MDS , AML CML 18 year age old may eligible study . Candidates screen medical history physical examination , blood test , chest x-ray , bone marrow aspirate biopsy . For bone marrow biopsy , area hip anesthetize special needle use draw marrow hipbone . Participants receive injection ( shot ) peptide vaccine deep tissue upper arm , upper leg , abdomen two separate shot sargramostim area vaccine shot . Patients ' vital sign ( heart rate , breathe rate , temperature , blood pressure ) measure receive vaccine watch 2 hour shot possible side effect , chill , pain injection site , stomach upset , allergic reaction , low blood count , infection . Patients return clinic 1 , 2 , 3 4 week receive vaccine brief physical evaluation blood test . A chest x-ray also do 4-week visit . Patients may receive whole blood platelet transfusion need treat MDS , growth factor ( filgrastim , erythropoietin , others ) need , medication treat infection may develop .</brief_summary>
	<brief_title>Safety Peptide Vaccination Patients With Myelodysplastic Syndrome</brief_title>
	<detailed_description>Myeloid malignancy include acute myeloid leukemia relate disorder myelodysplastic syndrome ( MDS ) myeloproliferative disease represent wide group bone marrow stem cell malignancy . Some patient cure chemotherapy allogeneic stem cell transplantation . However , proportion patient progress follow chemotherapy relapse transplantation . Therefore , need study investigational agent improve management patient . The immunological graft-versus-leukemia ( GVL ) effect see allogeneic stem cell transplantation suggest stimulate patient 's T cell response MDS leukemia vaccine might also retard disease progression even achieve disease remission . WT1 PR1 identify target antigen antigens highly express CD34+ stem cell patient myeloid malignancy normal marrow cell . An immunotherapeutic approach vaccinate PR1 WT1 antigen could induce T cell response MDS leukemic cell spar normal cell use combination two antigen risk disease escape antigen regulation diminish . Therefore , propose evaluate vaccine compose peptide derive two protein over-expressed MDS leukemia stem cell - proteinase 3 ( PR1 ) Wilms tumor-1 ( WT1 ) . This protocol , first series plan research , evaluate safety single dose combination two peptide vaccine , namely PR1:169-177 WT-1:126-134 Montanide adjuvant administer concomitantly GM-CSF ( Sargramostim ) select subject diagnose MDS , AML CML .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>INCLUSION CRITERIA : Diagnosed FAB subtypes RA , RARS MDS ( Low Risk ) OR Diagnosed AML complete remission within 5 year treatment less 5 percent marrow blast OR Diagnosed CML In chronic phase OR Diagnosed MDS , AML CML 6 months3 year follow allogeneic SCT fulfill follow criterion : 100 percent donor engraftment , less 5 percent blast marrow normal marrow cellularity HLAA0201 positive one allele Ages 18 85 year old EXCLUSION CRITERIA : Hypoplastic MDS Relapsed AML CML accelerate phase blast crisis Relapsed MDS , AML CML follow hematopoietic stem cell transplantation Hb le 9 g/dl , neutrophil count le 1 time 10 ( 9 ) /1 , and/ platelet count le 75 time 10 ( 9 ) /1 Hypocellular bone marrow History Wegener 's granulomatosis Serologic antibody proteinase3 ( ANCA positive ) Previous allergic reaction montanide adjuvant Positive test HIV Treatment systemic corticosteroid within 14 day prior study entry Comorbidity severity would preclude subject 's ability tolerate protocol therapy Predicted survival le 28 day Pregnant breast feeding ( All female subject must urine pregnancy test within 1 week prior vaccine administration ) Enrolled another drug vaccine clinical trial study period Inability comprehend investigational nature study provide inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 9, 2012</verification_date>
	<keyword>Myelodyplastic Syndrome ( MDS )</keyword>
	<keyword>Wilm 's tumor-1</keyword>
	<keyword>Proteinase-3</keyword>
	<keyword>Vaccine Therapy</keyword>
	<keyword>Acute Myeloid Leukemia</keyword>
	<keyword>Chronic Myeloid Leukemias</keyword>
	<keyword>Myelodysplastic Syndrome</keyword>
	<keyword>MDS</keyword>
</DOC>